← Russell 3000 cross-section

CLPT ClearPoint Neuro, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$505m
Revenue TTM
$42m
Net income TTM
$-35m
Free cash flow
$-31m
Composite score
31.6
Sector rank
#2395

Valuation

P / E
EV / EBITDA
EV / sales
12.4
FCF yield
-6.20%
Earnings yield vs 10-yr
-11.58pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-81.8%
EBITDA margin
-72.1%
ROE
-320.8%
ROIC
-98.1%
Revenue growth
25.9%

Insider activity, last 90 days

Net open-market
$-1.55m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue Recognition The Company’s revenue is comprised primarily of: (1) product revenue resulting from the sale of disposable products related to neurosurgery navigation, therapy, neurocritical care, and biologics and drug delivery, as well as ClearPoint and IRRA flow capital equipment and ClearPoint software; and (2) service revenue resulting from development services and consultation revenue in connection with customer-sponsored preclinical and clinical trials, as well as revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. …ClearPoint Neuro, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →